However, there is now sufficient evidence to recommend omalizumab as monotherapy for use in selected patients with IgE‐mediated food allergy, where there is a need to reduce the risk of food‐induced allergic reactions due to patient‐specific factors. This evidence concerns the gene IGHE and food allergy.